The market for treating arteriosclerosis obliterans is projected to expand steadily through 2036 across the United States, the UK, Japan, and the EU4 countries. With the United States currently holding the largest market share, industry focus is shifting toward moving beyond traditional symptom management. Current care relies heavily on agents like cilostazol, but clinical pipelines are increasingly populated by novel candidates aiming to improve vascular tone and facilitate tissue repair.

Key pharmaceutical players including Eli Lilly, Nippon Shinyaku, and Lisata Therapeutics are advancing new therapies such as Orforglipron and Selexipag. According to Aparna Thakur of DelveInsight, Selexipag is particularly notable for its potential to address intermittent claudication by enhancing blood flow. As these and other regenerative medicine approaches move through clinical trials, the medical community anticipates a transition toward more specialized, disease-modifying interventions that could significantly reduce amputation risks and improve patient quality of life.